Olivia J. Kelada

Olivia J. Kelada

Auto-generated profile, based on publicly available information

Olivia J. Kelada

Preclinical Imaging, PerkinElmer, Hopkinton, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2021 in Nature Materials
Verified
Journal Article
Open access
PDF file
LHLiangliang Hao
Liangliang Hao
NRNazanin Rohani
Nazanin Rohani
RZRenee T. Zhao
Renee T. Zhao
EPEmilia M. Pulver
Emilia M. Pulver
HMHoward Mak
Howard Mak
SBSangeeta N. Bhatia
Sangeeta N. Bhatia
Therapeutic outcomes in oncology may be aided by precision diagnostics that offer early detection, localization and the opportunity to monitor response to therapy. Here, we report a multimodal nanosensor engineered to target tumours through acidosis, respond to proteases in the microenvironment to release urinary reporters and (optionally) carry positron emission tomography probes to enable localization of primary and metastatic cancers in mouse models of colorectal cancer. We present a paradigm wherein this multimodal sensor can be employed longitudinally to assess burden of disease non-invasively, including tumour progression and response to chemotherapy. Specifically, we showed that acidosis-mediated tumour insertion enhanced on-target release of matrix metalloproteinase-responsive reporters in urine. Subsequent on-demand loading of the radiotracer 64Cu allowed pH-dependent tumour visualization, enabling enriched microenvironmental characterization when compared with the conventional metabolic tracer 18F-fluorodeoxyglucose. Through tailored target specificities, this modular platform has the capacity to be engineered as a pan-cancer test that may guide treatment decisions for numerous tumour types.

24 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NVNeeda A. Virani
Needa A. Virani
OKOlivia J. Kelada
Olivia J. Kelada
SKSijumon Kunjachan
Sijumon Kunjachan
ADAlexandre Detappe
Alexandre Detappe
JKJihun Kwon
Jihun Kwon
RBRoss I. Berbeco
Ross I. Berbeco
We have previously demonstrated that endothelial targeting of gold nanoparticles followed by external beam irradiation can cause specific tumor vascular disruption in mouse models of cancer. The induced vascular damage may lead to changes in tumor physiology, including tumor hypoxia, thereby compromising future therapeutic interventions. In this study, we investigate the dynamic changes in tumor hypoxia mediated by targeted gold nanoparticles and clinical radiation therapy (RT). By using noninvasive whole-body fluorescence imaging, tumor hypoxia was measured at baseline, on day 2 and day 13, post-tumor vascular disruption. A 2.5-fold increase (P<0.05) in tumor hypoxia was measured two days after combined therapy, resolving by day 13. In addition, the combination of vascular-targeted gold nanoparticles and radiation therapy resulted in a significant (P<0.05) suppression of tumor growth. This is the first study to demonstrate the tumor hypoxic physiological response and recovery after delivery of vascular-targeted gold nanoparticles followed by clinical radiation therapy in a human non-small cell lung cancer athymic Foxn1nu mouse model.